How the development of antiviral treatments for FIP transformed a once universally fatal disease, the welfare implications of treatment, and access challenges facing cat owners.
The emergence of effective antiviral treatment for FIP represents one of the most dramatic welfare advances in feline medicine in the past decade. Previously, FIP diagnosis was effectively a death sentence: the combination of immune dysregulation, severe inflammation, and organ involvement was universally fatal, and treatment was supportive only. The discovery that nucleoside analog antivirals could achieve durable remission transformed the prognosis of a disease that had caused enormous suffering and premature death in thousands of young cats annually. However, the treatment revolution has created new welfare inequities: the cost of treatment remains substantial, and access varies dramatically across countries depending on regulatory approval status. Cats whose owners cannot afford treatment face the same outcome as in the pre-treatment era — euthanasia or death from disease progression. The ethical imperative to make effective FIP treatment accessible is clear: a disease that can now be cured should be treated whenever diagnosis is confirmed and treatment is desired, with cost support mechanisms for owners facing financial barriers.